• A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer

  NCT02395016

  CompletedInterventionalPhase 3Updated Apr 4, 2024
• Nimotuzumab in Adults With Pancreatic Cancer

  NCT00561990

  CompletedInterventionalPhase 2Phase 3Updated Oct 15, 2015
• Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer

  NCT06409429

  Not yet recruitingInterventionalPhase 2Phase 3Updated May 10, 2024
• Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer

  NCT07277452

  Not yet recruitingInterventionalPhase 2Updated Dec 11, 2025
• Nimotuzumab Combined With Chemoradiotherapy in the Treatment of Unresectable Locally Advanced or Oligometastatic Pancreatic Cancer

  NCT07386704

  Enrolling by invitationInterventionalPhase 2Updated Feb 4, 2026
• Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer

  NCT06389760

  RecruitingInterventionalPhase 2Updated Oct 31, 2024

ClinicalTrials.gov ID

NCT02945267

Lead Sponsor

Chinese PLA General HospitalOTHER

Overall Status

Unknown status

Study Type

Interventional

Phase

Phase 4

Enrollment

60Estimated

Last Update Posted

Oct 26, 2016Estimated

Start Date

Sep 2016

Primary Completion Date

Dec 2018Estimated

Completion Date

Dec 2019Estimated

Official Title

A Randomized, Controlled, Double Blind, Multicenter Study of Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Advanced or Metastatic Pancreatic Cancer After First-line Treatment

Brief Summary

Background: Monotherapy with S-1, oral fluoropyrimidine, shows non-inferiority to gemcitabine in overall survival (OS) with good tolerability for advanced pancreatic cancer in Asian patients. It is also shown that nimotuzumab plus gemcitabine could improve OS and progression free survival (PFS) in patients with unresectable pancreatic cancer. However, it is still unknown whether nimotuzumab plus S1 would improve more to OS and PFS than single S-1. Maintenance treatment, as a new treatment pattern, has also been tried in these patients after first line treatment to improve the OS. Thus, this study is designed to compare nimotuzumab plus S1 to placebo plus S1 as maintenance treatment in patients with locally advanced or metastatic pancreatic cancer who has benefited from the first-line treatment of gemcitabine combined with nimotuzumab and S1 (complete response+partial response+stable disease).

Patients and methods: 60 patients will be enrolled,and randomized in a 1:1 ratio to group nimotuzumab plus S1 and group placebo plus S1. nimotuzumab/placebo: 400 mg/w, intravenous infusion, Infusion time ≥ 60 min, d1, once every two weeks. S1: oral, 40 mg (Body surface area<1.5 m2) or 60 mg (Body surface area>1.5 m2), d1-d14, every three weeks for a cycle. Treatment interventions will be stopped under the conditions of disease progression or intolerable toxic reaction or participants ask to quit. The primary endpoint is the time to disease progression since randomization (TTP), secondary points include OS, 3 years overall survival rate (OSR) and safety.

• Unresectable Pancreatic Cancer

• Nimotuzumab plus S1
• Placebo plus S1

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• 18-75 years;
• Karnofsky Performance Status≥ 60;
• histologically proven locally advanced or metastatic pancreatic cancer,and unsuitable for radiotherapy or surgery resection;
• benefited from the first line treatment of gemcitabine plus nimotuzumab and S1 (complete response+partial response+stable disease);
• at least 4 weeks from the end of the first-line treatment;
• with at least 1 measurable and evaluable lesion;
• anticipated over survival≥12 weeks;
• AST/ALT≤2.5 ULN (≤5 ULN for patients with hepatic metastases); total bilirubin≤2 ULN （≤3 ULN for patients with hepatic metastases); neutrophil count≥1.5×109/L; platelet counts≥100×109/L; hemoglobin level≥90 g/L; creatinine clearance rate≥ 60 mL/min
• written informed consent

Exclusion Criteria:

• previously received the following treatments: anticancer chemotherapy/molecularly targeted therapy as palliative treatment, or targeted chemotherapy and no progression, another interventional clinical trail within 4 weeks;
• underwent major surgery within 4 weeks;
• with brain or leptomeningeal metastases;
• history of malignancy other than pancreatic cancer;
• presented symptomatic abdominal fluid and needed treatment;
• with other serious diseases such as diabetes,active infection;
• known for allergy to anti epidermal growth factor receptor antibody

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

Double

Lead Sponsor

Chinese PLA General HospitalOTHER

18910883463

13341050946

18601949919

13811887990

huyi0401@aliyun.com13911031186